Vanda Pharmaceuticals Inc. Expected to Post Q3 2016 Earnings of ($0.09) Per Share (VNDA)
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Analysts at Jefferies Group issued their Q3 2016 earnings per share (EPS) estimates for Vanda Pharmaceuticals in a report issued on Thursday. Jefferies Group analyst M. Andrews expects that the firm will post earnings per share of ($0.09) for the quarter. Jefferies Group has a “Buy” rating and a $23.00 price objective on the stock. Jefferies Group also issued estimates for Vanda Pharmaceuticals’ Q4 2016 earnings at ($0.06) EPS, FY2016 earnings at ($0.54) EPS, FY2017 earnings at ($0.08) EPS, FY2018 earnings at $0.93 EPS, FY2019 earnings at $1.30 EPS and FY2020 earnings at $2.10 EPS.
Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings results on Wednesday, July 27th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.12. The company had revenue of $36.02 million for the quarter, compared to analyst estimates of $36.03 million. Vanda Pharmaceuticals had a negative net margin of 31.85% and a negative return on equity of 22.51%. The firm’s revenue was up 30.6% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.13) EPS.
Several other equities research analysts also recently commented on the stock. Piper Jaffray Cos. set a $16.00 price objective on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 18th. Zacks Investment Research raised shares of Vanda Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $14.00 price objective on the stock in a report on Tuesday, August 2nd. Brean Capital reaffirmed a “buy” rating and set a $24.00 price objective (up from $20.00) on shares of Vanda Pharmaceuticals in a report on Monday, August 29th. Finally, JMP Securities upped their price objective on shares of Vanda Pharmaceuticals from $18.00 to $22.00 and gave the company a “market outperform” rating in a report on Friday, August 26th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $20.00.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/10/vanda-pharmaceuticals-inc-expected-to-post-q3-2016-earnings-of-0-09-per-share-vnda.html
Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) opened at 16.83 on Monday. The company’s market capitalization is $728.47 million. Vanda Pharmaceuticals has a one year low of $6.91 and a one year high of $18.00. The company’s 50 day moving average is $15.55 and its 200 day moving average is $11.56.
Several large investors have recently made changes to their positions in VNDA. Bank of Montreal Can purchased a new stake in shares of Vanda Pharmaceuticals during the second quarter worth about $132,000. Acrospire Investment Management LLC bought a new position in Vanda Pharmaceuticals during the first quarter valued at $102,000. UBS Asset Management Americas Inc. boosted its position in Vanda Pharmaceuticals by 10.9% in the second quarter. UBS Asset Management Americas Inc. now owns 16,300 shares of the biopharmaceutical company’s stock valued at $182,000 after buying an additional 1,600 shares during the period. Paloma Partners Management Co bought a new position in Vanda Pharmaceuticals during the second quarter valued at $192,000. Finally, Jane Street Group LLC bought a new position in Vanda Pharmaceuticals during the second quarter valued at $200,000. 86.06% of the stock is currently owned by hedge funds and other institutional investors.
In other news, insider James E. Flynn sold 547,886 shares of the stock in a transaction dated Monday, September 19th. The shares were sold at an average price of $15.66, for a total value of $8,579,894.76. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider James E. Flynn sold 1,120,461 shares of the stock in a transaction dated Friday, September 23rd. The stock was sold at an average price of $16.56, for a total transaction of $18,554,834.16. The disclosure for this sale can be found here. 8.45% of the stock is currently owned by insiders.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051.
Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.